Teaching Case

Retroperitoneal Follicular Dendritic Cell Sarcoma: A Case Report

Cecilia Jiang, BA, a Yusef A. Syed, MD, b Elliott B. Burdette, MD, c David L. Jaye, MD, c,d Christopher R. Flowers, MD, d,e and Mohammad K. Khan, MD, PhD b,d,*

aEmory University School of Medicine, Emory University, Atlanta, Georgia; Departments of bRadiation Oncology, and cPathology and Laboratory Medicine, Emory University School of Medicine, Emory University, Atlanta, Georgia; dWinship Cancer Institute, Atlanta, Georgia; and eDepartment of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, Texas

Received 27 June 2019; revised 18 September 2019; accepted 2 December 2019

Introduction

Follicular dendritic cell sarcoma (FDCS) comprises 0.4% of soft tissue sarcomas.1 It most commonly relapses in the lungs and liver.2 In 1986, it was first described in a series of 4 case reports where management with wide local excisions and chemotherapy showed varying success.3 There have been limited studies on outcomes. A retrospective study of 31 patients with FDCS did not show significant differences in 5-year overall survival (OS) for patients who received adjuvant radiation or neoadjuvant chemotherapy compared with surgery alone (P = .58).4 For patients receiving adjuvant radiation, 30 to 63 Gy was delivered more than 30 to 35 fractions using intensity modulated radiation therapy.4 However, treatment protocols and results were not stratified by primary tumor location, and only 42% of cases primarily involved the abdomen.4 Another retrospective study on FDCS showed an association between consolidative adjuvant radiation therapy and improved local control, median progression-free survival, and OS; however, recurrences occurred in 14% of patients.5 Thus, there remains a lack of data on the role of radiation therapy in FDCS, particularly in the abdomen. Here, we present a patient with retroperitoneal FDCS successfully managed with surgery and adjuvant radiation.

Case Report

A 49-year-old man presented with abdominal discomfort in April 2012 found to be secondary to diverticulitis on computed tomography (CT) scan. He reported full resolution of his complaints after completing a treatment course for diverticulitis, denying night sweats, fever, weight loss, or abdominal discomfort. However, the CT scan incidentally revealed a retroperitoneal mass that was further imaged with magnetic resonance imaging and positron emission tomography (PET)/CT demonstrating an FDG avid 4.1 x 3.5 cm lesion in the celiac axis region. He underwent a gross total resection with regional lymphadenectomy of 2 enlarged lymph nodes on July 31, 2012. Margins were negative and the specimen measured 4.0 cm in diameter. His postoperative course was notable only for delayed wound healing treated with a course of antibiotics. Microscopic examination revealed a mass composed of loosely aggregated, heterogeneous spindle cells interspersed with small lymphocytes and focal fibrosis (Fig 1). Immunohistochemical stains were positive for CD21 (Fig 1 B), D240, and CD35 (weak) but negative for CD1a, CD34, S100, and HHV8, consistent with follicular...
dendritic cell differentiation. A few partly hyalinized foci contained atretic follicles consistent with Castleman disease (CD)—type changes, particularly the hyaline vascular variant (Fig 1 A, inset). The 2 lymph nodes failed to show pathologic abnormalities. When integrating pathology with the clinical and radiographic picture, the best fit was determined to be FDCS likely associated with unifocal CD.

After resection, the patient followed up with hematology-oncology, which led to multidisciplinary discussions. FDCS has been thought to fall along a spectrum from Hodgkin lymphoma to typical sarcoma, although it might more closely resemble low-grade soft tissue sarcomas than lymphoma. A restaging PET/CT and bone marrow biopsy were both negative. Based on literature, however, the patient possessed risk factors for local recurrence including abdominal location and surgical excision alone as primary therapy. Owing to his lack of residual disease and risk factors, hematology-oncology deferred management to radiation oncology.

According to literature, adjuvant radiation improved local control in both lymphoma and sarcoma patients. Based on 2 available case series, the patient was started on a 5.5-week radiation regimen to the preoperative PET-defined gross tumor volume with a 1.5-cm margin superiorly and inferiorly and a 1.0-cm margin radially. This region received 50.4 Gy in 28 fractions using 6 MV photons in a volumetric-modulated arc therapy technique (Fig 2). Dose constraints to organs at risk are shown in Table 1. He received radiation from October 22 to November 30, 2012, nearly 3 months after his excision. He tolerated this without side effects beyond grade 1 diarrhea and grade 1 nausea at the beginning and end of treatment, respectively, per Common Terminology Criteria for Adverse Events.

At 1-month follow-up, his clinical status was returning to baseline. Hematology-oncology opted to observe him given the definitive nature of the radiation. A PET/CT performed 2 months afterward revealed mildly increased uptake (SUV 2.5) in a subcutaneous nodule along the abdominal incision, interpreted as scar tissue. At 6- and 8-month follow-ups, he was back to baseline without weight loss, night sweats, lymphadenopathy, or pain. His Karnofsky Performance Status at these follow-ups was 100%. A repeat PET/CT 9 months afterward was negative for
malignancy. The patient was subsequently lost to follow-up.

**Discussion**

Here, we report a case of FDCS that was successfully treated with resection and adjuvant radiation. FDCS is a rare malignancy, with only 51 cases described in the English literature from 1986 to 1998.7 Our patient, a 49-year-old man, fits the observed demographic of FDCS, which has a median age of diagnosis of 47 years old and no sex preference.8 However, his disease was in the abdomen, whereas FDCS predominantly involves cervical lymph nodes.9

Management formerly consisted of definitive surgical excision with or without adjuvant treatment. Monda et al first reported 4 FDCS cases that all presented as painless unilateral cervical adenopathy.7 Of these cases, 1 was lost to follow-up, and another was successfully managed with a local excision. The other 2 experienced recurrences; one had a successful repeat wide local excision, and the other underwent repeat excisions and 5 rounds of adjuvant chemotherapy only to experience abdominal metastasis. She succumbed to her disease.

Since then, limited progress has been made in elucidating an optimal treatment regimen. Many clinicians have treated FDCS based on recommendations for high-grade soft tissue sarcomas where resection is the cornerstone of management. The literature indicates a 40% risk of recurrence and 28% risk of metastasis, prompting consideration of adjuvant therapy.10 Fonseca et al performed a review of 51 FDCS cases in the literature. Twelve of the 31 patients who underwent surgical resection alone experienced relapse compared with 2 of the 8 patients who also received radiation therapy; the 6 radiation patients who remained disease-free had a median disease-free survival of 36 months. This raised the idea that adjuvant radiation therapy could decrease recurrence.7

Adjuvant chemotherapy has been more controversial. In a case series of 17 patients, 7 patients were treated with adjuvant chemotherapy regimens most commonly featuring CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).10 Four experienced progression or recurrence within 2 years.10 Meanwhile, 2 patients treated with neoadjuvant CHOP experienced >95% tumor response and symptomatic improvement, respectively.10 Despite limited data, there may be a higher benefit to neoadjuvant systemic therapy. However, definitive diagnosis requires surgical pathology, CHOP is a standard lymphoma regimen, and advanced soft tissue sarcoma regimens such as CYVADIC (cyclophosphamide, vincristine, doxorubicin, dacarbazine) and gemcitabine and docetaxel have also been used.10-12 Higher intensity regimens may protect against progression, but outcomes with chemotherapy require more systematic comparisons to those without.

Indications for radiation are also controversial. A pooled analysis of FDCS case reports found no significant difference in OS in patients who received adjuvant radiation therapy compared with surgery alone (P = .474).13 However, neoadjuvant radiation therapy has resulted in good outcomes. One patient received 57.5 Gy to the oropharynx before a wide excision with radical neck dissection; they were disease free 4.5 years afterward.10 There are currently no treatment guidelines by the National Comprehensive Cancer Network. This is further complicated by variables such as tumor size >6 cm, >5 of 10 high-power fields mitotic count, and cellular atypia, which all have prognostic significance and lend a more heterogeneous import to FDCS.13

Of the patients with isolated local FDCS who received adjuvant radiation, there seems to be a threshold for effectiveness. One study evaluated 13 FDCS patients who received adjuvant radiation therapy to the resection bed with an additional 1 to 2 cm margin; they received a median dose of 50.4 Gy (range, 35-66 Gy) with significantly improved progression-free survival and OS compared with gross total resection only.8 Local relapses occurred in 2 patients who had received 39.6 Gy and 45 Gy of radiation.3 Taken together, these findings imply that higher dosages could increase effectiveness. This mirrors the findings of our patient, who received 50.4 Gy of intensity modulated radiation therapy.

Also, our patient’s histopathologic findings underscore a potential link between FDCS and CD.14 CD is a benign lymphoproliferative disorder involving interleukin 6.15 It can be classified as either multicentric or unicentric, and the hyaline vascular variant comprises 90% of unicentric CD.16 Ten percent to 20% of patients with FDCS have been found with the hyaline vascular variant of CD (HVCD), as with our patient.1 Demographically, however, he does not fit the average CD parameters featuring a female predominance and younger age range.17

Since 1986, there have limited cases of FDCS with CD, and the majority were intra-abdominal and involved

| Table 1: Dose constraints for designated organs at risk |
|-----------------------------|-----------------------------|
| Organ at risk   | Volume | Dose limit |
|-----------------|--------|------------|
| Left kidney     | 100%   | ≤15 Gy     |
| Left kidney     | 50%    | ≤20 Gy     |
| Left kidney     | 25%    | ≤25 Gy     |
| Right kidney    | 100%   | ≤15 Gy     |
| Right kidney    | 50%    | ≤20 Gy     |
| Right kidney    | 25%    | ≤25 Gy     |
| Liver           | 50%    | ≤30 Gy     |
| Liver           | 25%    | ≤45 Gy     |
| Small bowel     | 50%    | ≤45 Gy     |
| Spinal cord     | 100%   | ≤45 Gy     |
| Stomach         | 100%   | ≤55 Gy     |
| Esophagus       | 100%   | ≤55 Gy     |
HVCD.\(^8\) This is consistent with our patient. Chan et al published the first case report of a patient with FDCS transforming from HVCD. He had initially presented with a nasopharyngeal mass that was biopsied showing HVCD with focal FDC overgrowth.\(^8\) Years later, the mass recurred, and biopsy revealed FDCS in the setting of focal HVCD. After undergoing excision, 3 cycles of adjuvant CHOP, and a nasopharyngectomy, the patient was disease-free at 3-year follow-up.\(^8\) However, this case differs from ours in disease locality, and thus management cannot be directly extrapolated.

Hwang et al described a case of concurrent abdominal CD and FDCS where a patient had a 5-cm peripancreatic lymph node revealed as FDCS in a background of focal residual CD.\(^8\) This was resected and she underwent adjuvant radiation therapy consisting of 45 Gy over 5 weeks with no recurrence at 9 month follow-up. Our patient was similarly diagnosed with abdominal FDCS with features suggestive of CD, and he also underwent 50.4 Gy of adjuvant radiation therapy and was disease-free at 9 months. These cases demonstrate that for intra-abdominal HVCD and FDCS, adjuvant radiation therapy in the range of 45 to 51 Gy has a potential benefit, although the degree is uncertain owing to a lack of controls and loss to follow-up. Radiation therapy is potentially sufficient as the sole adjuvant therapy, which is advantageous because it has fewer side effects compared with chemotherapy. Our patient did not develop toxicities beyond class 1 nausea and vomiting.

In summary, this is a rare case of intra-abdominal FDCS with features of HVCD that was successfully managed with surgical excision and adjuvant radiation therapy. With new cases, studies elucidating the role of radiation therapy are recommended.

References

1. Yan WX, Yu YX, Zhang P, Liu XK, Li Y. Follicular dendritic cell sarcoma detected in hepatogastric ligament: A case report and review of the literature. World J Clin Cases. 2019;7:116-121.
2. Kairouz S, Hashash J, Kabbara W, McHayleh W, Tabbar IA. Dendritic cell neoplasms: An overview. Am J Hematol. 2007;82:924-928.
3. Monda L, Wamke R, Rosai A J. Primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am J Pathol. 1986;122:562-572.
4. Gounder M, Desai V, Kuk D, et al. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. Eur J Cancer. 2015;51:2413-2422.
5. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Hematol. 2017;178:403-412.
6. Perez-Ordóñez B, Erlandson RA, Rosai J. Follicular dendritic cell tumor: Report of 13 additional cases of a distinctive entity. Am J Surg Pathol. 1996;20:944-955.
7. Fonseca R, Yamakawa M, Nakamura S, et al. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review. Am J Hematol. 1998;59:161-167.
8. Hwang SO, Lee TH, Bae SH, et al. Transformation of Castleman's disease into follicular dendritic cell sarcoma, presenting as an asymptomatic intra-abdominal mass. Korean J Gastroenterol. 2013;62:131-134.
9. Cakir E, Aydin NE, Samdanci E, et al. Follicular dendritic cell sarcoma associated with hyaline-vascular Castleman's disease. J Pak Med Assoc. 2013;63:393-395.
10. Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma. Clinopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer. 1997;79:294-313.
11. Chen HM, Shen YL, Liu M. Primary hepatic follicular dendritic cell sarcoma: A case report. World J Clin Cases. 2019;7:785-791.
12. Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397-1410.
13. Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N. Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;88:253-271.
14. McDonough MJ, Feldmeier JJ, Parsai I, Dobelbower RR Jr, Selman SH. Salvage external beam radiotherapy for clinical failure after cryosurgery for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:624-627.
15. Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014;21:266-278.
16. Westphal FL, Lima LC, Santana LC, et al. Castleman's disease associated with follicular dendritic cell sarcoma and myasthenia gravis. J Bras Pneumol. 2010;36:819-823.
17. Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am. 2018;32:1-10.
18. Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman's disease of the nasopharynx: Tracing its evolution by sequential biopsies. Histopathology. 2001;38:510-518.